X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/european-medicines-agency-validates-pierre-fabre-laboratories-marketing-authorisation-application-for-combination-braftovi-encorafenib-and-mektovi-binimetinib-for-patients-with-brafv600-mutant-advanced-non-small-cell-lung-c-301975614.html
https://www.onclive.com/view/encorafenib-binimetinib-combo-highlights-novel-therapies-for-braf-v600-nsclc
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-19-2023-50304.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-mektovi-binimetinib-1661948789.pdf
https://www.globenewswire.com/news-release/2022/06/02/2455007/0/en/OnKure-Therapeutics-Announces-First-Patient-Dosed-in-the-Phase-1b-2-Nautilus-Trial-of-OKI-179-in-Combination-with-Binimetinib-in-Patients-with-Advanced-NRAS-Mutated-Melanoma.html
https://www.pmlive.com/pharma_news/eortc_and_pierre_fabre_launch_phase_3_trial_for_melanoma_1449323
https://www.eortc.org/blog/2022/05/24/pierre-fabre-and-eortc-open-a-large-phase-iii-clinical-study-in-the-adjuvant-setting-of-stage-iib-c-melanoma/
https://www.prnewswire.com/news-releases/ideaya-announces-dose-expansion-in-phase-12-study-of-ide196-and-binimetinib-combination-in-metastatic-uveal-melanoma-based-on-early-clinical-activity-301253392.html
https://www.prnewswire.com/news-releases/ideaya-biosciences-doses-first-patient-in-a-phase-1-combination-study-of-ide196-and-binimetinib-a-mek-inhibitor-301090539.html
https://www.prnewswire.com/news-releases/ideaya-biosciences-doses-first-patient-in-a-phase-1-combination-study-of-ide196-and-binimetinib-a-mek-inhibitor-301090539.html
http://www.pharmatimes.com/news/ema_validates_bratovi,_mektovi_application_for_some_mcrc_1315939
http://www.pharmatimes.com/news/hse_reimburses_braftovi_combo_1298971
http://www.pharmafile.com/news/524241/pierre-fabres-triplet-therapy-makes-strong-showing-braf-v600e-mutant-metastatic-colorect
https://www.biospace.com/article/array-biopharma-s-triple-drug-combo-could-be-gamechanger-for-colorectal-cancer/
https://www.businesswire.com/news/home/20190706005001/en/Pierre-Fabre-partner-Array-BioPharma-announce-interim
https://www.fiercepharma.com/pharma/array-played-pfizer-s-eagerness-to-land-a-deal-time-and-got-itself-a-better-offer
https://endpts.com/right-back-at-you-pfizer-beigene-and-a-pfizer-spinout-launch-a-newco-to-develop-a-mek-braf-inhibitor-that-could-rival-11-4b-combo/
https://www.prnewswire.com/news-releases/array-biopharma-announces-presentation-of-updated-overall-survival-from-the-phase-3-columbus-trial-of-braftovi--mektovi-in-advanced-brafmutant-melanoma-at-2019-asco-annual-meeting-300858355.html
https://www.reuters.com/article/us-array-biopharma-study/array-biopharmas-colorectal-cancer-combo-treatment-meets-main-goals-idUSKCN1SR1AE
http://www.pharmafile.com/news/522388/array-biopharmas-braftovi-triple-therapy-meets-both-endpoints-advanced-colorectal-cancer
https://www.prnewswire.com/news-releases/braftovi-encorafenib-in-combination-with-mektovi-binimetinib-and-erbitux-cetuximab-or-panitumumab-recommended-by-the-national-comprehensive-cancer-network-nccn-guidelines-as-a-treatment-option-for-patients-with-advance-300813829.html
https://www.ema.europa.eu/documents/product-information/mektovi-epar-product-information_en.pdf
http://www.pharmatimes.com/news/eu_approves_new_option_for_metastatic_melanoma_1253166
https://www.fiercebiotech.com/research/unraveling-mysteries-drug-resistance-melanoma-crispr-cas9
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/07/news_detail_002994.jsp&mid=WC0b01ac058004d5c1
https://www.prnewswire.com/news-releases/the-national-comprehensive-cancer-network-nccn-guidelines-recommend-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-as-a-category-1-treatment-option-for-patients-with-advanced-braf-mutant-melanoma-300680562.html
https://www.fiercepharma.com/ready-to-challenge-novartis-and-roche-array-scores-fda-nod-for-melanoma-combo
https://www.businesswire.com/news/home/20180604005578/en/Pierre-Fabre-Partner-Array-BioPharma-Announce-Additional
Market Place
Share 
